Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen panitumumab gets fast-track status

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Amgen's epidermal growth factor receptor inhibitor panitumumab gets fast-track designation for treatment of metastatic colorectal cancer patients who have failed standard chemotherapy, the company announces Aug. 1. Amgen plans to initiate the BLA "by the end of 2005"; "the completed submission of the BLA could extend into the first quarter of 2006, depending on timing and outcome of clinical data." Prior to the fast-track designation, Amgen indicated it would submit panitumumab in the second half of 2005 (1Pharmaceutical Approvals Monthly April 2005, In Brief)...

You may also be interested in...

Amgen/Abgenix’ Panitumumab Slows Colorectal Cancer Progression By 46%

Amgen's pivotal Phase III study of panitumumab for third-line metastatic colorectal cancer treatment showed a highly statistically significant 46% decrease in tumor progression rate compared to best supportive care (p<0.000000001)

Amgen preps panitumumab NDA

Amgen plans to submit its epidermal growth factor receptor inhibitor panitumumab in the second half of 2005 for treatment of third-line colorectal cancer, the firm says March 29. Two Phase III trials, one each in the U.S. and EU, are ongoing. "In recent discussions with the FDA, we have obtained favorable opinion regarding the acceptability of these studies for U.S. registration," Senior Director-Licensing Anthony Gringeri, PhD, tells investors at the Smith Barney Citigroup Healthcare conference. Amgen maintains the monoclonal antibody has advantages over Bristol-Myers Squibb/ImClone's EGFR agent Erbitux (cetuximab), including "fewer infusion reactions"...

Vaccine Experts Inject Realism Into US Gov't's COVID-19 Timeline

The Trump administration says a COVID-19 vaccine could be available in as little as 12 months, but most experts think that is overpromising unless safety or efficacy standards are sacrificed. Many are urging pivotal studies that look at clinical outcomes, not surrogates, for US FDA approval. 





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts